The termination of the collaboration with Genentech and F. Hoffman-La Roche, two significant players in the pharmaceutical industry, could be perceived negatively by investors. This partnership was likely viewed as a key driver for future growth and innovation for Adaptimmune, and its end might raise concerns about the company's future prospects and ability to secure similar agreements.